FOR PRESCRIBERS & CLINICS
Your Specialty Pharmacy Partner for Behavioral Health Injectables
At Patriot Pharmacy, we support clinics and prescribers managing long-acting injectable antipsychotics for patients living with psychosis-related conditions. Our specialty process is built to fit your workflow, so the people you serve can stay on therapy with fewer access delays.
Long-acting injectable (LAI) antipsychotics can help improve adherence and reduce relapse risk compared with daily oral therapy when consistency is hard to maintain. Patriot offers personalized specialty pharmacy support focused on timely access, coordinated delivery, and dependable scheduling around administration.
Dependable access. Clinic-ready coordination.
Why providers choose Patriot for behavioral health injectable support:
Stronger adherence support
– LAIs remove the burden of daily dosing. We help keep starts, refills, and administration timing aligned so therapy stays continuous.
Seamless delivery process
– We coordinate delivery to your clinic or care setting so medication arrives when your team is ready to administer, not days off schedule.
Administration-site support
– Patriot can support injectable administration pathways for eligible therapies, helping your patients complete treatment without unnecessary handoffs.
Schedule consistency that reduces waste
– Missed or poorly timed LAI fulfillment can lead to wasted product and disrupted care. We prioritize consistent refill and delivery timing to protect product integrity and avoid preventable waste.
Efficient prior authorization
– Our specialty team helps navigate coverage requirements and reduce the back-and-forth that delays injection appointments.
Clear care-team communication
– We share status updates quickly so your office can resolve issues before they interrupt administration.
Learn More
Benefits of Behavioral Health Injectable Specialty Support
Every patient should receive respectful, steady care. As your local specialty pharmacy partner, Patriot Pharmacy works with your care team to help patients receive long-acting injectable therapy on time and remain supported between doses.
We partner with you to:
- Ease administrative burden on your staff
- Improve access to critical long-acting injectable antipsychotics
- Streamline prior authorizations and benefits investigation
- Coordinate delivery around administration schedules
- Maintain refill consistency to reduce missed doses and unnecessary drug waste
- Support adherence beyond the first injection
Specialty Medications for Behavioral Health Injectables
Patriot Pharmacy supports access to critical and often difficult-to-coordinate long-acting injectable antipsychotics used in the treatment of psychosis-related conditions, including schizophrenia and schizoaffective disorder. These medications are administered by a licensed healthcare professional on a scheduled basis.
Abilify Maintena®
(aripiprazole extended-release injectable suspension)
A long-acting injectable atypical antipsychotic used in the management of schizophrenia and related conditions, administered by a healthcare professional on a scheduled basis.
Abilify Asimtufii®
(aripiprazole extended-release injectable suspension)
A longer-interval aripiprazole LAI option that supports extended dosing schedules when clinically appropriate.
Aristada®
(aripiprazole lauroxil extended-release injectable suspension)
A long-acting aripiprazole formulation with flexible dosing intervals, administered by a healthcare professional.
Invega Sustenna®
(paliperidone palmitate extended-release injectable suspension)
A once-monthly long-acting injectable antipsychotic used in the treatment of schizophrenia in adults.
Invega Trinza®
(paliperidone palmitate extended-release injectable suspension, 3-month)
A every-three-month paliperidone LAI option for eligible patients previously stabilized on monthly therapy.
Invega Hafyera®
(paliperidone palmitate extended-release injectable suspension, 6-month)
A every-six-month paliperidone LAI option for eligible patients meeting transition criteria from shorter-interval therapy.
Risperdal Consta®
(risperidone long-acting injection)
A long-acting risperidone injectable used in schizophrenia and related conditions, administered on a scheduled basis by a healthcare professional.
Perseris®
(risperidone extended-release injectable suspension)
A subcutaneous long-acting risperidone option administered by a healthcare professional.
Expert Care and Support for Complex Medication Needs
Explore Our Specialty Pharmacy Services
From prior authorizations to personalized counseling, Patriot Pharmacy’s specialty services are built to support patients with chronic or complex conditions. Our streamlined process, clinical expertise, and ACHC-accredited standards help make specialty medications easier to manage for both patients and providers.
References
National Institute of Mental Health. (n.d.). Schizophrenia. Retrieved July 24, 2026, from https://www.nimh.nih.gov/health/publications/schizophrenia
National Institute of Mental Health. (n.d.). Mental health medications. Retrieved July 24, 2026, from https://www.nimh.nih.gov/health/topics/mental-health-medications
American Psychiatric Association. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia (3rd ed.). Retrieved July 24, 2026, from https://www.psychiatry.org/psychiatrists/practice/clinical-practice-guidelines
American Psychiatric Association. (n.d.). Position statement on long-acting injectable antipsychotics in early psychotic illness. Retrieved July 24, 2026, from https://www.psychiatry.org/about-apa/policy-finder/position-statement-on-long-acting-injectable-antip
National Alliance on Mental Illness. (n.d.). Long-acting injectables (LAIs). Retrieved July 24, 2026, from https://www.nami.org/treatments-and-approaches/mental-health-medications/long-acting-injectables-lais/
Kaplan, G., Casoy, J., & Zummo, J. (2013). Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Preference and Adherence, 7, 1171–1180. Retrieved July 24, 2026, from https://pmc.ncbi.nlm.nih.gov/articles/PMC3833623/
U.S. Food and Drug Administration. (2025). ABILIFY MAINTENA (aripiprazole) for extended-release injectable suspension [Prescribing information]. Retrieved July 24, 2026, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202971s018,217006s001lbl.pdf
U.S. Food and Drug Administration. (2024). RISPERDAL CONSTA (risperidone) long-acting injection [Prescribing information]. Retrieved July 24, 2026, from https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021346s052Lbl.pdf
